Decoy Therapeutics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Decoy Therapeutics Inc. is a preclinical biopharmaceutical company focused on the discovery and development of peptide-conjugate therapeutics leveraging its IMP3ACT platform to streamline drug design, synthesis, and manufacturing for rapid antiviral and oncology programs. The company operates primarily in the United States and Europe, with a strategic emphasis on global access and scalable manufacturing capabilities to support rapid progression from preclinical stages toward clinical development. Decoy Therapeutics is headquartered in Paris, Île-de-France, France, and founders date to its rebranding and NASDAQ listing as Decoy Therapeutics (ticker DCOY) following the merger that transformed Salarius Pharmaceuticals into its current corporate structure in 2024. The firm maintains a portfolio approach, developing intranasal and systemic peptide-conjugate therapies designed to target respiratory viruses and cancer indications, with a core emphasis on building platform-based capabilities that enable rapid iteration, optimization, and potential future commercialization. Key activities include platform research using machine learning and AI-assisted design, peptide synthesis and conjugation manufacturing, and strategic collaborations to validate and scale its therapeutic candidates. The company’s business model centers on platform monetization through partnerships, joint development agreements, and potential future license or sale of developed assets, alongside ongoing investment in platform expansion, manufacturing scale-up, and pipeline advancement. Decoy Therapeutics places particular emphasis on global access initiatives, aiming to couple scientifically innovative antiviral and oncologic therapeutics with scalable production and distribution frameworks across multiple regions. The company’s current product focus encompasses pan-coronavirus antiviral programs, broad-acting antivirals for influenza and other respiratory pathogens, and peptide-drug conjugates for GI and oncology applications, with ongoing exploratory work to expand its therapeutic pipeline as it advances toward clinical filings and potential regulatory approvals.
Company News
Decoy Therapeutics to Present at The Small Cap Showcase
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript